Agios, UPenn announce cancer Dx collaboration
CAMBRIDGE, Mass.—Agios Pharmaceuticals and the University of Pennsylvania have announced that their organizations would be establishing a licensing agreement revolving around new intellectual property focused on developing diagnostic products to detect certain cancers' metabolisms. The agreement comes in connection with the resolution of certain litigation, with the result that the established agreement will dismiss both cases entirely. Financial details were not disclosed.
"We are pleased to be moving forward in a collaborative manner around newly identified intellectual property. We look forward to working with Agios on this project and potentially other unrelated projects in the future," Dr. Chi Van Dang, professor of medicine and director of the Abramson Cancer Center at UPenn, said in a press release.